newsfilter
← Latest News
GlobeNewswire·

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose